MicroRNA and heart failure

International Journal of Molecular Sciences

Volumn 17, Issue 4, 2016, Pages

  Wong, Lee Lee ^a   Wang, Juan ^a   Liew, Oi Wah ^a   Richards, Arthur Mark ^a,b,c   Chen, Yei Tsung ^a  

^a Dept Medicine Endocrinol Diabet   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cardiovascular; Heart failure; MicroRNA; Neurohormone

Indexed keywords

CAPADENOSON; DICER; MICRORNA; MICRORNA 1; MICRORNA 100; MICRORNA 107; MICRORNA 122; MICRORNA 1246; MICRORNA 1254; MICRORNA 126; MICRORNA 133A; MICRORNA 133B; MICRORNA 142 3P; MICRORNA 15; MICRORNA 17; MICRORNA 17 5P; MICRORNA 183 3P; MICRORNA 18A; MICRORNA 195; MICRORNA 208A; MICRORNA 208B; MICRORNA 20A; MICRORNA 499; MICRORNA 92A; MICRORNA 92B; MINERALOCORTICOID ANTAGONIST; MYOSIN HEAVY CHAIN ALPHA; NEUROHORMONE; SPIRONOLACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; HORMONE;

APOPTOSIS; BIOGENESIS; CLINICAL TRIAL (TOPIC); GENE EXPRESSION; GENE TARGETING; HEART ARRHYTHMIA; HEART DEVELOPMENT; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; HEART FAILURE; HORMONES; HUMANS; MICRORNAS; SIGNAL TRANSDUCTION;

EID: 84962869314     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17040502     Document Type: Review

References (180)

1. Eric, J.; Topol, R.M.C. Textbook of Cardiovascular Medicine; Lippincott Williams & Wilkins: New York, NY, USA, 2007.
2. Vogel, B.; Keller, A.; Frese, K.S.; Leidinger, P.; Sedaghat-Hamedani, F.; Kayvanpour, E.; Kloos, W.; Backe, C.; Thanaraj, A.; Brefort, T.; et al. Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. Eur. Heart J. 2013, 34, 2812–2822.
3. Song, W.; Wang, H.; Wu, Q. Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene 2015, 569, 1–6.
4. Yandle, T.G.; Richards, A.M. B-type Natriuretic Peptide circulating forms: Analytical and bioactivity issues. Clin. Chim. Acta 2015, 448, 195–205.
5. Rademaker, M.T.; Cameron, V.A.; Charles, C.J.; Lainchbury, J.G.; Nicholls, M.G.; Richards, A.M. Adrenomedullin and heart failure. Regul. Pept. 2003, 112, 51–60.
6. Vardeny, O.; Miller, R.; Solomon, S.D. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014, 2, 663–670.
7. Montgomery, R.L.; Hullinger, T.G.; Semus, H.M.; Dickinson, B.A.; Seto, A.G.; Lynch, J.M.; Stack, C.; Latimer, P.A.; Olson, E.N.; van Rooij, E. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011, 124, 1537–1547.
8. Van Rooij, E.; Olson, E.N. MicroRNA therapeutics for cardiovascular disease: Opportunities and obstacles. Nat. Rev. Drug Discov. 2012, 11, 860–872.
9. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843–854.
10. Wightman, B.; Ha, I.; Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75, 855–862.
11. Bentwich, I.; Avniel, A.; Karov, Y.; Aharonov, R.; Gilad, S.; Barad, O.; Barzilai, A.; Einat, P.; Einav, U.; Meiri, E.; et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat. Genet. 2005, 37, 766–770.
12. Kozomara, A.; Griffiths-Jones, S. MiRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014, 42, D68–D73.
13. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509–524.
14. Therapeutics, M. A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection. Available online: https://www.clinicaltrials.gov/ct2/show/NCT01829971?term=mirna+therapeutics&rank =115 (accessed on 3 December 2015).
15. Species Tree. Available online: http://www.ensembl.org/info/about/speciestree.html (accessed on 29 September 2015).
16. Olena, A.F.; Patton, J.G. Genomic organization of microRNAs. J. Cell. Physiol. 2010, 222, 540–545.
17. Rodriguez, A.; Griffiths-Jones, S.; Ashurst, J.L.; Bradley, A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004, 14, 1902–1910.
18. Lee, Y.; Kim, M.; Han, J.; Yeom, K.H.; Lee, S.; Baek, S.H.; Kim, V.N. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004, 23, 4051–4060.
19. Kim, V.N.; Han, J.; Siomi, M.C. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 2009, 10, 126–139.
20. Pillai, R.S. MicroRNA function: Multiple mechanisms for a tiny RNA? RNA 2005, 11, 1753–1761.
21. Ambros, V. The functions of animal microRNAs. Nature 2004, 431, 350–355.
22. Hausser, J.; Zavolan, M. Identification and consequences of miRNA-target interactions—Beyond repression of gene expression. Nat. Rev. Genet. 2014, 15, 599–612.
23. Cai, X.; Hagedorn, C.H.; Cullen, B.R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004, 10, 1957–1966.
24. Leuschner, P.J.; Ameres, S.L.; Kueng, S.; Martinez, J. Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep. 2006, 7, 314–320.
25. Hata, A. Functions of microRNAs in cardiovascular biology and disease. Annu. Rev. Physiol. 2013, 75, 69–93.
26. Novak, J.; Olejnickova, V.; Tkacova, N.; Santulli, G. Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis. Adv. Exp. Med. Biol. 2015, 887, 79–100.
27. Latronico, M.V.; Condorelli, G. MicroRNAs and cardiac pathology. Nat. Rev. Cardiol. 2009, 6, 419–429.
28. Park, C.Y.; Choi, Y.S.; McManus, M.T. Analysis of microRNA knockouts in mice. Hum. Mol. Genet. 2010, 19, R169–R175.
29. Santulli, G.; Iaccarino, G.; de Luca, N.; Trimarco, B.; Condorelli, G. Atrial fibrillation and microRNAs. Front. Physiol. 2014, 5, 15.
30. Wronska, A.; Kurkowska-Jastrzebska, I.; Santulli, G. Application of microRNAs in diagnosis and treatment of cardiovascular disease. Acta Physiol. (Oxf.) 2015, 213, 60–83.
31. Ono, K. MicroRNAs and Cardiovascular Remodeling. Adv. Exp. Med. Biol. 2015, 888, 197–213.
32. Gnecchi, M.; Pisano, F.; Bariani, R. MicroRNA and Cardiac Regeneration. Adv. Exp. Med. Biol. 2015, 887, 119–141.
33. Bernstein, E.; Kim, S.Y.; Carmell, M.A.; Murchison, E.P.; Alcorn, H.; Li, M.Z.; Mills, A.A.; Elledge, S.J.; Anderson, K.V.; Hannon, G.J. Dicer is essential for mouse development. Nat. Genet. 2003, 35, 215–217.
34. Liu, J.; Carmell, M.A.; Rivas, F.V.; Marsden, C.G.; Thomson, J.M.; Song, J.J.; Hammond, S.M.; Joshua-Tor, L.; Hannon, G.J. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004, 305, 1437–1441.
35. Kanellopoulou, C.; Muljo, S.A.; Kung, A.L.; Ganesan, S.; Drapkin, R.; Jenuwein, T.; Livingston, D.M.; Rajewsky, K. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev. 2005, 19, 489–501.
36. Saxena, A.; Tabin, C.J. miRNA-processing enzyme Dicer is necessary for cardiac outflow tract alignment and chamber septation. Proc. Natl. Acad. Sci. USA 2010, 107, 87–91.
37. Chen, J.F.; Murchison, E.P.; Tang, R.; Callis, T.E.; Tatsuguchi, M.; Deng, Z.; Rojas, M.; Hammond, S.M.; Schneider, M.D.; Selzman, C.H.; et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc. Natl. Acad. Sci. USA 2008, 105, 2111–2116.
38. Da Costa Martins, P.A.; Bourajjaj, M.; Gladka, M.; Kortland, M.; van Oort, R.J.; Pinto, Y.M.; Molkentin, J.D.; de Windt, L.J. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008, 118, 1567–1576.
39. Chen, J.F.; Mandel, E.M.; Thomson, J.M.; Wu, Q.; Callis, T.E.; Hammond, S.M.; Conlon, F.L.; Wang, D.Z. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 2006, 38, 228–233.
40. Wystub, K.; Besser, J.; Bachmann, A.; Boettger, T.; Braun, T. miR-1/133a clusters cooperatively specify the cardiomyogenic lineage by adjustment of myocardin levels during embryonic heart development. PLoS Genet. 2013, 9, e1003793.
41. Zhao, Y.; Samal, E.; Srivastava, D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005, 436, 214–220.
42. Zhao, Y.; Ransom, J.F.; Li, A.; Vedantham, V.; von Drehle, M.; Muth, A.N.; Tsuchihashi, T.; McManus, M.T.; Schwartz, R.J.; Srivastava, D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1–2. Cell 2007, 129, 303–317.
43. Ikeda, S.; He, A.; Kong, S.W.; Lu, J.; Bejar, R.; Bodyak, N.; Lee, K.H.; Ma, Q.; Kang, P.M.; Golub, T.R.; et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol. Cell. Biol. 2009, 29, 2193–2204.
44. Liu, N.; Bezprozvannaya, S.; Williams, A.H.; Qi, X.; Richardson, J.A.; Bassel-Duby, R.; Olson, E.N. MicroRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008, 22, 3242–3254.
45. Biyashev, D.; Veliceasa, D.; Topczewski, J.; Topczewska, J.M.; Mizgirev, I.; Vinokour, E.; Reddi, A.L.; Licht, J.D.; Revskoy, S.Y.; Volpert, O.V. miR-27b controls venous specification and tip cell fate. Blood 2012, 119, 2679–2687.
46. Chinchilla, A.; Lozano, E.; Daimi, H.; Esteban, F.J.; Crist, C.; Aranega, A.E.; Franco, D. MicroRNA profiling during mouse ventricular maturation: A role for miR-27 modulating Mef2c expression. Cardiovasc. Res. 2011, 89, 98–108.
47. Wang, H.R.; Wu, M.; Yu, H.; Long, S.; Stevens, A.; Engers, D.W.; Sackin, H.; Daniels, J.S.; Dawson, E.S.; Hopkins, C.R.; et al. Selective inhibition of the Kir2 family of inward rectifier potassium channels by a small molecule probe: The discovery, SAR, and pharmacological characterization of ML133. ACS Chem. Biol. 2011, 6, 845–856.
48. Callis, T.E.; Pandya, K.; Seok, H.Y.; Tang, R.H.; Tatsuguchi, M.; Huang, Z.P.; Chen, J.F.; Deng, Z.; Gunn, B.; Shumate, J.; et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Investig. 2009, 119, 2772–2786.
49. Wilson, K.D.; Hu, S.; Venkatasubrahmanyam, S.; Fu, J.D.; Sun, N.; Abilez, O.J.; Baugh, J.J.; Jia, F.; Ghosh, Z.; Li, R.A.; et al. Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: Role for miR-499. Circ. Cardiovasc. Genet. 2010, 3, 426–435.
50. Sluijter, J.P.; van Mil, A.; van Vliet, P.; Metz, C.H.; Liu, J.; Doevendans, P.A.; Goumans, M.J. MicroRNA-1 and-499 regulate differentiation and proliferation in human-derived cardiomyocyte progenitor cells. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 859–868.
51. Porrello, E.R.; Johnson, B.A.; Aurora, A.B.; Simpson, E.; Nam, Y.J.; Matkovich, S.J.; Dorn, G.W., 2nd; van Rooij, E.; Olson, E.N. miR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ. Res. 2011, 109, 670–679.
52. Porrello, E.R.; Mahmoud, A.I.; Simpson, E.; Johnson, B.A.; Grinsfelder, D.; Canseco, D.; Mammen, P.P.; Rothermel, B.A.; Olson, E.N.; Sadek, H.A. Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. Proc. Natl. Acad. Sci. USA 2013, 110, 187–192.
53. Kuhnert, F.; Mancuso, M.R.; Hampton, J.; Stankunas, K.; Asano, T.; Chen, C.Z.; Kuo, C.J. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 2008, 135, 3989–3993.
54. Wang, S.; Aurora, A.B.; Johnson, B.A.; Qi, X.; McAnally, J.; Hill, J.A.; Richardson, J.A.; Bassel-Duby, R.; Olson, E.N. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 2008, 15, 261–271.
55. Fish, J.E.; Santoro, M.M.; Morton, S.U.; Yu, S.; Yeh, R.F.; Wythe, J.D.; Ivey, K.N.; Bruneau, B.G.; Stainier, D.Y.; Srivastava, D. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 2008, 15, 272–284.
56. Harris, T.A.; Yamakuchi, M.; Ferlito, M.; Mendell, J.T.; Lowenstein, C.J. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc. Natl. Acad. Sci. USA 2008, 105, 1516–1521.
57. Doebele, C.; Bonauer, A.; Fischer, A.; Scholz, A.; Reiss, Y.; Urbich, C.; Hofmann, W.K.; Zeiher, A.M.; Dimmeler, S. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 2010, 115, 4944–4950.
58. Mogilyansky, E.; Rigoutsos, I. The miR-17/92 cluster: A comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013, 20, 1603–1614.
59. Bonauer, A.; Carmona, G.; Iwasaki, M.; Mione, M.; Koyanagi, M.; Fischer, A.; Burchfield, J.; Fox, H.; Doebele, C.; Ohtani, K.; et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009, 324, 1710–1713.
60. Santulli, G. MicroRNAs and Endothelial (Dys) Function. J. Cell. Physiol. 2015.
61. Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr.; Drazner, M.H.; Fonarow, G.C.; Geraci, S.A.; Horwich, T.; Januzzi, J.L.; et al. 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128, 1810–1852.
62. Alla, F.; Zannad, F.; Filippatos, G. Epidemiology of acute heart failure syndromes. Heart Fail. Rev. 2007, 12, 91–95.
63. Stewart, S.; MacIntyre, K.; Hole, D.J.; Capewell, S.; McMurray, J.J. More “malignant” than cancer? Five-year survival following a first admission for heart failure. Eur. J. Heart Fail. 2001, 3, 315–322.
64. Heidenreich, P.A.; Albert, N.M.; Allen, L.A.; Bluemke, D.A.; Butler, J.; Fonarow, G.C.; Ikonomidis, J.S.; Khavjou, O.; Konstam, M.A.; Maddox, T.M.; et al. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ. Heart Fail. 2013, 6, 606–619.
65. Goyal, A.; Norton, C.R.; Thomas, T.N.; Davis, R.L.; Butler, J.; Ashok, V.; Zhao, L.; Vaccarino, V.; Wilson, P.W. Predictors of incident heart failure in a large insured population: A one million person-year follow-up study. Circ. Heart Fail. 2010, 3, 698–705.
66. Lam, C.S.; Lyass, A.; Kraigher-Krainer, E.; Massaro, J.M.; Lee, D.S.; Ho, J.E.; Levy, D.; Redfield, M.M.; Pieske, B.M.; Benjamin, E.J.; et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 2011, 124, 24–30.
67. Roger, V.L. Epidemiology of heart failure. Circ. Res. 2013, 113, 646–659.
68. Owan, T.E.; Hodge, D.O.; Herges, R.M.; Jacobsen, S.J.; Roger, V.L.; Redfield, M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 2006, 355, 251–259.
69. Bhatia, R.S.; Tu, J.V.; Lee, D.S.; Austin, P.C.; Fang, J.; Haouzi, A.; Gong, Y.; Liu, P.P. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. 2006, 355, 260–269.
70. Hogg, K.; Swedberg, K.; McMurray, J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J. Am. Coll. Cardiol. 2004, 43, 317–327.
71. Schrier, R.W.; Abraham, W.T. Hormones and hemodynamics in heart failure. N. Engl. J. Med. 1999, 341, 577–585.
72. Zois, N.E.; Bartels, E.D.; Hunter, I.; Kousholt, B.S.; Olsen, L.H.; Goetze, J.P. Natriuretic peptides in cardiometabolic regulation and disease. Nat. Rev. Cardiol. 2014, 11, 403–412.
73. Samson, W.K. Adrenomedullin and the control of fluid and electrolyte homeostasis. Annu. Rev. Physiol. 1999, 61, 363–389.
74. Emeto, T.I.; Moxon, J.V.; Rush, C.; Woodward, L.; Golledge, J. Relevance of urocortins to cardiovascular disease. J. Mol. Cell. Cardiol. 2011, 51, 299–307.
75. Fluck, D.C. Catecholamines. Br. Heart J. 1972, 34, 869–873.
76. Lefkowitz, R.J.; Rockman, H.A.; Koch, W.J. Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation 2000, 101, 1634–1637.
77. Spinarova, L.; Vitovec, J. Neurohumoral changes in chronic heart failure. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2007, 151, 201–207.
78. Attina, T.; Camidge, R.; Newby, D.E.; Webb, D.J. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 2005, 91, 825–831.
79. Potter, L.R.; Abbey-Hosch, S.; Dickey, D.M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 2006, 27, 47–72.
80. Rademaker, M.T.; Richards, A.M. Cardiac natriuretic peptides for cardiac health. Clin. Sci. (Lond.) 2005, 108, 23–36.
81. Braunwald, E. Biomarkers in heart failure. N. Engl. J. Med. 2008, 358, 2148–2159.
82. Rademaker, M.T.; Charles, C.J.; Richards, A.M. Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, H1536–H1544.
83. Davis, M.E.; Pemberton, C.J.; Yandle, T.G.; Fisher, S.F.; Lainchbury, J.G.; Frampton, C.M.; Rademaker, M.T.; Richards, A.M. Urocortin 2 infusion in healthy humans: Hemodynamic, neurohormonal, and renal responses. J. Am. Coll. Cardiol. 2007, 49, 461–471.
84. Nishikimi, T.; Miyata, A.; Horio, T.; Yoshihara, F.; Nagaya, N.; Takishita, S.; Yutani, C.; Matsuo, H.; Matsuoka, H.; Kangawa, K. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am. J. Physiol. Heart Circ. Physiol. 2000, 279, H3031–H3039.
85. McMurray, J.J.; Adamopoulos, S.; Anker, S.D.; Auricchio, A.; Bohm, M.; Dickstein, K.; Falk, V.; Filippatos, G.; Fonseca, C.; Gomez-Sanchez, M.A.; et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2012, 14, 803–869.
86. Klip, I.T.; Voors, A.A.; Anker, S.D.; Hillege, H.L.; Struck, J.; Squire, I.; van Veldhuisen, D.J.; Dickstein, K.; investigators, O. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart 2011, 97, 892–898.
87. Van Veldhuisen, D.J.; Linssen, G.C.; Jaarsma, T.; van Gilst, W.H.; Hoes, A.W.; Tijssen, J.G.; Paulus, W.J.; Voors, A.A.; Hillege, H.L. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J. Am. Coll. Cardiol. 2013, 61, 1498–1506.
88. Lipshultz, S.E.; Rifai, N.; Sallan, S.E.; Lipsitz, S.R.; Dalton, V.; Sacks, D.B.; Ottlinger, M.E. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997, 96, 2641–2648.
89. Adams, J.E., 3rd; Bodor, G.S.; Davila-Roman, V.G.; Delmez, J.A.; Apple, F.S.; Ladenson, J.H.; Jaffe, A.S. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993, 88, 101–106.
90. Hayashida, K.; Kume, N.; Murase, T.; Minami, M.; Nakagawa, D.; Inada, T.; Tanaka, M.; Ueda, A.; Kominami, G.; Kambara, H.; et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: A novel marker for early diagnosis. Circulation 2005, 112, 812–818.
91. Semigran, M.; Shin, J.T. Heart Failure, 2nd ed.; CRC Press: Boca Raton, FL, USA, 2013; p. 1.
92. Gaggin, H.K.; Januzzi, J.L., Jr. Biomarkers and diagnostics in heart failure. Biochim. Biophys. Acta 2013, 1832, 2442–2450.
93. Troughton, R.W.; Frampton, C.M.; Brunner-La Rocca, H.P.; Pfisterer, M.; Eurlings, L.W.; Erntell, H.; Persson, H.; O’Connor, C.M.; Moertl, D.; Karlstrom, P.; et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: An individual patient meta-analysis. Eur. Heart J. 2014, 35, 1559–1567.
94. Richards, A.M. The natriuretic peptides in heart failure. Basic Res. Cardiol. 2004, 99, 94–100.
95. Januzzi, J.L.; van Kimmenade, R.; Lainchbury, J.; Bayes-Genis, A.; Ordonez-Llanos, J.; Santalo-Bel, M.; Pinto, Y.M.; Richards, M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur. Heart J. 2006, 27, 330–337.
96. Fuat, A.; Murphy, J.J.; Hungin, A.P.; Curry, J.; Mehrzad, A.A.; Hetherington, A.; Johnston, J.I.; Smellie, W.S.; Duffy, V.; Cawley, P. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br. J. Gen. Pract. 2006, 56, 327–333.
97. Christenson, R.H.; Azzazy, H.M.; Duh, S.H.; Maynard, S.; Seliger, S.L.; Defilippi, C.R. Impact of increased body mass index on accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP for diagnosis of decompensated heart failure and prediction of all-cause mortality. Clin. Chem. 2010, 56, 633–641.
98. Richards, M.; Di Somma, S.; Mueller, C.; Nowak, R.; Peacock, W.F.; Ponikowski, P.; Mockel, M.; Hogan, C.; Wu, A.H.; Clopton, P.; et al. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: Results from the BACH Study (Biomarkers in ACute Heart Failure). JACC Heart Fail. 2013, 1, 192–199.
99. Rahimtoola, S.H. Digitalis therapy for patients in clinical heart failure. Circulation 2004, 109, 2942–2946.
100. Ambrosy, A.P.; Butler, J.; Ahmed, A.; Vaduganathan, M.; van Veldhuisen, D.J.; Colucci, W.S.; Gheorghiade, M. The use of digoxin in patients with worsening chronic heart failure: Reconsidering an old drug to reduce hospital admissions. J. Am. Coll. Cardiol. 2014, 63, 1823–1832.
101. Yusuf, S.; Pfeffer, M.A.; Swedberg, K.; Granger, C.B.; Held, P.; McMurray, J.J.; Michelson, E.L.; Olofsson, B.; Ostergren, J.; Investigators, C. Committees, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003, 362, 777–781.
102. Massie, B.M.; Carson, P.E.; McMurray, J.J.; Komajda, M.; McKelvie, R.; Zile, M.R.; Anderson, S.; Donovan, M.; Iverson, E.; Staiger, C.; et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 2008, 359, 2456–2467.
103. Capuano, A.; Scavone, C.; Vitale, C.; Sportiello, L.; Rossi, F.; Rosano, G.M.; Coats, A.J. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Int. J. Cardiol. 2015, 200, 15–19.
104. Pitt, B.; Pfeffer, M.A.; Assmann, S.F.; Boineau, R.; Anand, I.S.; Claggett, B.; Clausell, N.; Desai, A.S.; Diaz, R.; Fleg, J.L.; et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 2014, 370, 1383–1392.
105. Pfeffer, M.A.; Claggett, B.; Assmann, S.F.; Boineau, R.; Anand, I.S.; Clausell, N.; Desai, A.S.; Diaz, R.; Fleg, J.L.; Gordeev, I.; et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015, 131, 34–42.
106. Kristensen, S.L.; Kober, L.; Jhund, P.S.; Solomon, S.D.; Kjekshus, J.; McKelvie, R.S.; Zile, M.R.; Granger, C.B.; Wikstrand, J.; Komajda, M.; et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation 2015, 131, 43–53.
107. Rossignol, P.; Zannad, F. Regional differences in heart failure with preserved ejection fraction trials: When nephrology meets cardiology but east does not meet west. Circulation 2015, 131, 7–10.
108. Richards, A.M. Therapeutic potential of infused cardiac natriuretic peptides in myocardial infarction. Heart 2009, 95, 1299–1300.
109. Nishikimi, T.; Maeda, N.; Matsuoka, H. The role of natriuretic peptides in cardioprotection. Cardiovasc. Res. 2006, 69, 318–328.
110. Filippatos, G.; Farmakis, D.; Parissis, J.; Lekakis, J. Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: In need of a new paradigm of LCZ696 implementation in clinical practice. BMC Med. 2015, 13, 35.
111. Bayes-Genis, A.; Barallat, J.; Galan, A.; de Antonio, M.; Domingo, M.; Zamora, E.; Urrutia, A.; Lupon, J. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J. Am. Coll. Cardiol. 2015, 65, 657–665.
112. Minguet, J.; Sutton, G.; Ferrero, C.; Gomez, T.; Bramlage, P. LCZ696: A new paradigm for the treatment of heart failure? Expert Opin. Pharmacother. 2015, 16, 435–446.
113. Von Lueder, T.G.; Krum, H. New medical therapies for heart failure. Nat. Rev. Cardiol. 2015, 12, 730–740.
114. Aronson, D.; Krum, H. Novel therapies in acute and chronic heart failure. Pharmacol. Ther. 2012, 135, 1–17.
115. Mitrovic, V.; Seferovic, P.M.; Simeunovic, D.; Ristic, A.D.; Miric, M.; Moiseyev, V.S.; Kobalava, Z.; Nitsche, K.; Forssmann, W.G.; Luss, H.; et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur. Heart J. 2006, 27, 2823–2832.
116. Lee, C.Y.; Chen, H.H.; Lisy, O.; Swan, S.; Cannon, C.; Lieu, H.D.; Burnett, J.C., Jr. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J. Clin. Pharmacol. 2009, 49, 668–673.
117. Lapp, H.; Mitrovic, V.; Franz, N.; Heuer, H.; Buerke, M.; Wolfertz, J.; Mueck, W.; Unger, S.; Wensing, G.; Frey, R. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 2009, 119, 2781–2788.
118. Ponikowski, P.; Mitrovic, V.; Ruda, M.; Fernandez, A.; Voors, A.A.; Vishnevsky, A.; Cotter, G.; Milo, O.; Laessing, U.; Zhang, Y.; et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur. Heart J. 2014, 35, 431–441.
119. Chan, W.Y.; Frampton, C.M.; Crozier, I.G.; Troughton, R.W.; Richards, A.M. Urocortin-2 infusion in acute decompensated heart failure: Findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy). JACC Heart Fail. 2013, 1, 433–441.
120. Rademaker, M.T.; Charles, C.J.; Ellmers, L.J.; Lewis, L.K.; Nicholls, M.G.; Richards, A.M. Prolonged urocortin 2 administration in experimental heart failure: Sustained hemodynamic, endocrine, and renal effects. Hypertension 2011, 57, 1136–1144.
121. Davis, M.E.; Pemberton, C.J.; Yandle, T.G.; Fisher, S.F.; Lainchbury, J.G.; Frampton, C.M.; Rademaker, M.T.; Richards, M. Urocortin 2 infusion in human heart failure. Eur. Heart J. 2007, 28, 2589–2597.
122. Liu, X.; Gu, X.; Li, Z.; Li, X.; Li, H.; Chang, J.; Chen, P.; Jin, J.; Xi, B.; Chen, D.; et al. Neuregulin-1/ erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J. Am. Coll. Cardiol. 2006, 48, 1438–1447.
123. Tarigopula, M.; Davis, R.T., 3rd; Mungai, P.T.; Ryba, D.M.; Wieczorek, D.F.; Cowan, C.L.; Violin, J.D.; Wolska, B.M.; Solaro, R.J. Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, TRV120023, in a dilated cardiomyopathy model. Cardiovasc. Res. 2015, 107, 226–234.
124. Boerrigter, G.; Soergel, D.G.; Violin, J.D.; Lark, M.W.; Burnett, J.C., Jr. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ. Heart Fail. 2012, 5, 627–634.
125. Sabbah, H.N.; Gupta, R.C.; Kohli, S.; Wang, M.; Rastogi, S.; Zhang, K.; Zimmermann, K.; Diedrichs, N.; Albrecht-Kupper, B.E. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ. Heart Fail. 2013, 6, 563–571.
126. Dawson, K.; Wakili, R.; Ordog, B.; Clauss, S.; Chen, Y.; Iwasaki, Y.; Voigt, N.; Qi, X.Y.; Sinner, M.F.; Dobrev, D.; et al. MicroRNA29: A mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 2013, 127, 1466–1475, 1475e1–28.
127. Eitel, I.; Adams, V.; Dieterich, P.; Fuernau, G.; de Waha, S.; Desch, S.; Schuler, G.; Thiele, H. Relation of circulating microRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. Am. Heart J. 2012, 164, 706–714.
128. Watson, C.J.; Gupta, S.K.; O’Connell, E.; Thum, S.; Glezeva, N.; Fendrich, J.; Gallagher, J.; Ledwidge, M.; Grote-Levi, L.; McDonald, K.; et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur. J. Heart Fail. 2015, 17, 405–415.
129. Wong, L.L.; Armugam, A.; Sepramaniam, S.; Karolina, D.S.; Lim, K.Y.; Lim, J.Y.; Chong, J.P.; Ng, J.Y.; Chen, Y.T.; Chan, M.M.; et al. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur. J. Heart Fail. 2015, 17, 393–404.
130. Ellis, K.L.; Cameron, V.A.; Troughton, R.W.; Frampton, C.M.; Ellmers, L.J.; Richards, A.M. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur. J. Heart Fail. 2013, 15, 1138–1147.
131. Tijsen, A.J.; Creemers, E.E.; Moerland, P.D.; de Windt, L.J.; van der Wal, A.C.; Kok, W.E.; Pinto, Y.M. MiR423-5p as a circulating biomarker for heart failure. Circ. Res. 2010, 106, 1035–1039.
132. Endo, K.; Naito, Y.; Ji, X.; Nakanishi, M.; Noguchi, T.; Goto, Y.; Nonogi, H.; Ma, X.; Weng, H.; Hirokawa, G.; et al. MicroRNA 210 as a biomarker for congestive heart failure. Biol. Pharm. Bull. 2013, 36, 48–54.
133. Zhang, R.; Niu, H.; Ban, T.; Xu, L.; Li, Y.; Wang, N.; Sun, L.; Ai, J.; Yang, B. Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction. Int. J. Cardiol. 2013, 166, 259–260.
134. Fukushima, Y.; Nakanishi, M.; Nonogi, H.; Goto, Y.; Iwai, N. Assessment of plasma miRNAs in congestive heart failure. Circ. J. 2011, 75, 336–340.
135. Corsten, M.F.; Dennert, R.; Jochems, S.; Kuznetsova, T.; Devaux, Y.; Hofstra, L.; Wagner, D.R.; Staessen, J.A.; Heymans, S.; Schroen, B. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ. Cardiovasc. Genet. 2010, 3, 499–506.
136. Matsumoto, S.; Sakata, Y.; Suna, S.; Nakatani, D.; Usami, M.; Hara, M.; Kitamura, T.; Hamasaki, T.; Nanto, S.; Kawahara, Y.; et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ. Res. 2013, 113, 322–326.
137. Goren, Y.; Kushnir, M.; Zafrir, B.; Tabak, S.; Lewis, B.S.; Amir, O. Serum levels of microRNAs in patients with heart failure. Eur. J. Heart Fail. 2012, 14, 147–154.
138. Xiao, J.; Jing, Z.C.; Ellinor, P.T.; Liang, D.; Zhang, H.; Liu, Y.; Chen, X.; Pan, L.; Lyon, R.; Liu, Y.; et al. MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J. Transl. Med. 2011, 9, 159.
139. Zhao, D.S.; Chen, Y.; Jiang, H.; Lu, J.P.; Zhang, G.; Geng, J.; Zhang, Q.; Shen, J.H.; Zhou, X.; Zhu, W.; et al. Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure. Cardiovasc. Pathol. Off. J. Soc. Cardiovasc. Pathol. 2013, 22, 444–450.
140. Goren, Y.; Meiri, E.; Hogan, C.; Mitchell, H.; Lebanony, D.; Salman, N.; Schliamser, J.E.; Amir, O. Relation of reduced expression of miR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure. Am. J. Cardiol. 2014, 113, 976–981.
141. Wei, X.J.; Han, M.; Yang, F.Y.; Wei, G.C.; Liang, Z.G.; Yao, H.; Ji, C.W.; Xie, R.S.; Gong, C.L.; Tian, Y. Biological significance of miR-126 expression in atrial fibrillation and heart failure. Braz. J. Med. Biol. Res. 2015, 48, 983–989.
142. Lai, K.B.; Sanderson, J.E.; Izzat, M.B.; Yu, C.M. Micro-RNA and mRNA myocardial tissue expression in biopsy specimen from patients with heart failure. Int. J. Cardiol. 2015, 199, 79–83.
143. Qiang, L.; Hong, L.; Ningfu, W.; Huaihong, C.; Jing, W. Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients. Int. J. Cardiol. 2013, 168, 2082–2088.
144. Gidlof, O.; Smith, J.G.; Miyazu, K.; Gilje, P.; Spencer, A.; Blomquist, S.; Erlinge, D. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovasc. Disord. 2013, 13, 12.
145. Nair, N.; Kumar, S.; Gongora, E.; Gupta, S. Circulating miRNA as novel markers for diastolic dysfunction. Mol. Cell. Biochem. 2013, 376, 33–40.
146. Voellenkle, C.; van Rooij, J.; Cappuzzello, C.; Greco, S.; Arcelli, D.; Di Vito, L.; Melillo, G.; Rigolini, R.; Costa, E.; Crea, F.; et al. MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients. Physiol. Genom. 2010, 42, 420–426.
147. Naga Prasad, S.V.; Duan, Z.H.; Gupta, M.K.; Surampudi, V.S.; Volinia, S.; Calin, G.A.; Liu, C.G.; Kotwal, A.; Moravec, C.S.; Starling, R.C.; et al. Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J. Biol. Chem. 2009, 284, 27487–27499.
148. Sucharov, C.; Bristow, M.R.; Port, J.D. miRNA expression in the failing human heart: Functional correlates. J. Mol. Cell. Cardiol. 2008, 45, 185–192.
149. Duan, Q.; Chen, C.; Yang, L.; Li, N.; Gong, W.; Li, S.; Wang, D.W. MicroRNA regulation of unfolded protein response transcription factor XBP1 in the progression of cardiac hypertrophy and heart failure in vivo. J. Transl. Med. 2015, 13, 363.
150. Da Costa Martins, P.A.; DeWindt, L.J. MicroRNAs in control of cardiac hypertrophy. Cardiovasc. Res. 2012, 93, 563–572.
151. Pan, Z.; Sun, X.; Ren, J.; Li, X.; Gao, X.; Lu, C.; Zhang, Y.; Sun, H.; Wang, Y.; Wang, H.; et al. miR-1 exacerbates cardiac ischemia-reperfusion injury in mouse models. PLoS ONE 2012, 7, e50515.
152. Pan, W.; Zhong, Y.; Cheng, C.; Liu, B.; Wang, L.; Li, A.; Xiong, L.; Liu, S. miR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy. PLoS ONE 2013, 8, e53950.
153. Thum, T.; Gross, C.; Fiedler, J.; Fischer, T.; Kissler, S.; Bussen, M.; Galuppo, P.; Just, S.; Rottbauer, W.; Frantz, S.; et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456, 980–984.
154. Sayed, D.; He, M.; Hong, C.; Gao, S.; Rane, S.; Yang, Z.; Abdellatif, M. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J. Biol. Chem. 2010, 285, 20281–20290.
155. Zhu, H.; Yang, Y.; Wang, Y.; Li, J.; Schiller, P.W.; Peng, T. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovasc. Res. 2011, 92, 75–84.
156. Wang, J.; Jia, Z.; Zhang, C.; Sun, M.; Wang, W.; Chen, P.; Ma, K.; Zhang, Y.; Li, X.; Zhou, C. miR-499 protects cardiomyocytes from H2O2-induced apoptosis via its effects on Pdcd4 and Pacs2. RNA Biol. 2014, 11, 339–350.
157. Zhang, B.; Zhou, M.; Li, C.; Zhou, J.; Li, H.; Zhu, D.; Wang, Z.; Chen, A.; Zhao, Q. MicroRNA-92a inhibition attenuates hypoxia/reoxygenation-induced myocardiocyte apoptosis by targeting Smad7. PLoS ONE 2014, 9, e100298.
158. Wong, L.L.; Wee, A.S.; Lim, J.Y.; Ng, J.Y.; Chong, J.P.; Liew, O.W.; Lilyanna, S.; Martinez, E.C.; Ackers-Johnson, M.A.; Vardy, L.A.; et al. Natriuretic peptide receptor 3 (NPR3) is regulated by microRNA-100. J. Mol. Cell. Cardiol. 2015, 82, 13–21.
159. Li, D.; Yang, P.; Xiong, Q.; Song, X.; Yang, X.; Liu, L.; Yuan, W.; Rui, Y.C. MicroRNA-125a/b-5p inhibits endothelin-1 expression in vascular endothelial cells. J. Hypertens. 2010, 28, 1646–1654.
160. Eskildsen, T.V.; Schneider, M.; Sandberg, M.B.; Skov, V.; Bronnum, H.; Thomassen, M.; Kruse, T.A.; Andersen, D.C.; Sheikh, S.P. The microRNA-132/212 family fine-tunes multiple targets in Angiotensin II signalling in cardiac fibroblasts. J. Renin Angiotensin Aldosterone Syst. 2015, 16, 1288–1297.
161. Kotlo, K.U.; Hesabi, B.; Danziger, R.S. Implication of microRNAs in atrial natriuretic peptide and nitric oxide signaling in vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 2011, 301, C929–C937.
162. Rane, S.; He, M.; Sayed, D.; Yan, L.; Vatner, D.; Abdellatif, M. An antagonism between the AKT and _-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p. Cell Signal. 2010, 22, 1054–1062.
163. Martin, M.M.; Lee, E.J.; Buckenberger, J.A.; Schmittgen, T.D.; Elton, T.S. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J. Biol. Chem. 2006, 281, 18277–18284.
164. Arora, P.; Wu, C.; Khan, A.M.; Bloch, D.B.; Davis-Dusenbery, B.N.; Ghorbani, A.; Spagnolli, E.; Martinez, A.; Ryan, A.; Tainsh, L.T.; et al. Atrial natriuretic peptide is negatively regulated by microRNA-425. J. Clin. Investig. 2013, 123, 3378–3382.
165. Maharjan, S.; Mopidevi, B.; Kaw, M.K.; Puri, N.; Kumar, A. Human aldosterone synthase gene polymorphism promotes miRNA binding and regulates gene expression. Physiol. Genom. 2014, 46, 860–865.
166. Agarwal, V.; Bell, G.W.; Nam, J.W.; Bartel, D.P. Predicting effective microRNA target sites in mammalian mRNAs. Elife 2015, 4, e05005.
167. TargetScan Human Prediction of MicroRNA Targets. Available online: http://www.targetscan.org/ (acceseed on 3 December 2015).
168. Wong, N.; Wang, X. MiRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015, 43, D146–D152.
169. MiRDB. Available online: http://mirdb.org/miRDB/ (accessed on 3 December 2015).
170. Betel, D.; Koppal, A.; Agius, P.; Sander, C.; Leslie, C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 2010, 11, R90.
171. MicroRNA.org-Targets and Expression. Available online: http://www.microrna.org/microrna/home.do (accessed on 3 December 2015).
172. Brennecke, J.; Stark, A.; Russell, R.B.; Cohen, S.M. Principles of microRNA-target recognition. PLoS Biol. 2005, 3, e85.
173. Yue, D.; Liu, H.; Huang, Y. Survey of Computational Algorithms for MicroRNA Target Prediction. Curr. Genom. 2009, 10, 478–492.
174. Janssen, H.L.; Reesink, H.W.; Lawitz, E.J.; Zeuzem, S.; Rodriguez-Torres, M.; Patel, K.; van der Meer, A.J.; Patick, A.K.; Chen, A.; Zhou, Y.; et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368, 1685–1694.
175. Bader, A.G. miR-34—A microRNA replacement therapy is headed to the clinic. Front. Genet. 2012, 3, 120.
176. Santaris Pharma A/S. Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C. Available online: https://clinicaltrials.gov/show/NCT01727934 (accessed on 3 December 2015).
177. Cloonan, N.; Wani, S.; Xu, Q.; Gu, J.; Lea, K.; Heater, S.; Barbacioru, C.; Steptoe, A.L.; Martin, H.C.; Nourbakhsh, E.; et al. MicroRNAs and their isomiRs function cooperatively to target common biological pathways. Genome Biol. 2011, 12, R126.
178. Zhang, Y.; Wang, Z.; Gemeinhart, R.A. Progress in microRNA delivery. J. Control. Release 2013, 172, 962–974.
179. Ko, Y.T.; Hartner, W.C.; Kale, A.; Torchilin, V.P. Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther. 2009, 16, 52–59.
180. Kwekkeboom, R.F.; Lei, Z.; Doevendans, P.A.; Musters, R.J.; Sluijter, J.P. Targeted delivery of miRNA therapeutics for cardiovascular diseases: Opportunities and challenges. Clin. Sci. (Lond.) 2014, 127, 351–365.